Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy

References

• Bokhorst LP, Valdagni R, Rannikko A, et al. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol. 2016;70:954–960.
   PubMed Web of Science ®Google Scholar
• Klotz L. Active surveillance for low-risk prostate cancer. Curr Urol Rep. 2015;16:24.
   PubMed Web of Science ®Google Scholar
• Sahibzada I, Batura D, Hellawell G. Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance. Int Urol Nephrol. 2016;48:529–533.
   PubMed Web of Science ®Google Scholar
• Wong AT, Safdieh JJ, Rineer J, et al. A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer. Int Urol Nephrol. 2015;47:1629–1634.
   PubMed Web of Science ®Google Scholar
• Sooriakumaran P, Srivastava A, Christos P, et al. Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer. Int Urol Nephrol. 2012;44:459–470.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981–990.
   PubMed Web of Science ®Google Scholar
• Kim TH, Jeon HG, Choo SH, et al. Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols. Int J Urol. 2014;21:377–381.
   PubMed Web of Science ®Google Scholar
• Fascelli M, George AK, Frye T, et al. The role of MRI in active surveillance for prostate cancer. Curr Urol Rep. 2015;16:42.
   PubMed Web of Science ®Google Scholar
• Pepe P, Garufi A, Priolo G, et al. Prostate cancer detection at repeat biopsy: can pelvic phased-array multiparametric MRI replace saturation biopsy? Anticancer Res. 2013;33:1195–1199.
   PubMed Web of Science ®Google Scholar
• Pepe P, Garufi A, Priolo G, Pennisi M. Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA <10 ng/mL? Clin Genitourin Cancer. 2015;13:e27–e30.
   PubMed Web of Science ®Google Scholar
• Guo R, Cai L, Fan Y, et al. Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis. Prostate Cancer Prostatic Dis. 2015;18:221–228.
   PubMed Web of Science ®Google Scholar
• Pepe P, Dibenedetto G, Pennisi M, et al. Detection rate of anterior prostate cancer in 226 patients submitted to initial and repeat transperineal biopsy. Urol Int. 2014;93:189–192.
   PubMed Web of Science ®Google Scholar
• Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology. 2007;70:1131–1135.
   PubMed Web of Science ®Google Scholar
• Tyson MD, Arora SS, Scarpato KR, et al. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol. 2016;34:326–332.
   PubMed Web of Science ®Google Scholar
• Cantiello F, Russo GI, Cicione A, et al. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol. 2016;34:485–493.
   PubMed Web of Science ®Google Scholar
• Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66:550–560.
   PubMed Web of Science ®Google Scholar
• Russo GI, Castelli T, Favilla V, et al. Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria. Prostate Cancer Prostatic Dis. 2015;18:338–342.
   PubMed Web of Science ®Google Scholar
• Chung PH, Darwish OM, Roehrborn CG, et al. Histologic upgrading in patients eligible for active surveillance on saturation biopsy. Can J Urol. 2015;22:7656–7660.
   PubMed Web of Science ®Google Scholar
• Abouassaly R, Lane BR, Jones JS. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology. 2008;71:573–577.
   PubMed Web of Science ®Google Scholar
• Thompson JE, Hayen A, Landau A, et al. Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. BJU Int. 2015;115:884–891.
   PubMed Web of Science ®Google Scholar
• Perera M, Katelaris N, Murphy D, et al. PI-RADS 4 or more: active surveillance no more. BJU Int. 2017;119:9–12.
   PubMed Web of Science ®Google Scholar
• Vos LJ, Janoski M, Wachowicz K, et al. Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance. WJR. 2016;8:410–418.
   Google Scholar
• Ouzzane A, Renard-Penna R, Marliere F, et al. magnetic resonance imaging targeted biopsy improves selection of patients considered for active surveillance for clinically low risk prostate cancer based on systematic biopsies. J Urol. 2015;194:350–356.
   PubMed Web of Science ®Google Scholar
• Pham KN, Porter CR, Odem-Davis K, et al. Transperineal template guided prostate biopsy selects candidates for active surveillance–how many cores are enough? J Urol. 2015;194:674–679.
   PubMed Web of Science ®Google Scholar
• Kamrava M, Kishan AU, Margolis DJ, et al. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Pract Radiat Oncol. 2015;5:411–416.
   PubMedGoogle Scholar
• Satasivam P, Poon BY, Ehdaie B, et al. Can confirmatory biopsy be omitted in patients with prostate cancer favorable diagnostic features on active surveillance? J Urol. 2016;195:74–79.
   PubMed Web of Science ®Google Scholar
• Pepe P, Aragona F. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology. 2013;81:1142–1146.
   PubMed Web of Science ®Google Scholar
• Pepe P, Garufi A, Priolo G, et al. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance? World J Urol. 2016;34:1249–1253.
   PubMed Web of Science ®Google Scholar
• Matsugasumi T, Baco E, Palmer S, et al. Prostate cancer volume estimation by combining magnetic resonance imaging and targeted biopsy proven cancer core length: correlation with cancer volume. J Urol. 2015;194:957–965.
   PubMed Web of Science ®Google Scholar